Abu Dhabi Investment Authority (ADIA) is taking a significant minority stake in Hologic Inc. The Marlborough, Massachusetts-based company is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world.
ADIA is part of the consortium that is taking the company private. It includes funds managed by Blackstone and TPG. The transaction is valued at up to US$79 per share, representing an enterprise value of up to US$18.3 billion.
The transaction is expected to close in the first half of calendar year 2026, subject to the approval of Hologic’s stockholders, other regulatory approvals and satisfaction of certain customary closing conditions. It has been unanimously approved by the Hologic Board of Directors, which has recommended that stockholders vote their shares to approve the transaction and adopt the merger agreement.
Hologic delivered full-year revenue of US$4.03 billion for 2024, and issued guidance of increasing it to US$4.15 billion to US$4.2 billion for FY2025. Following the announcement of the transaction, the company plans to report its financial results for the fourth quarter of fiscal 2025 on November 3. However, it does not intend to provide financial guidance for fiscal 2026 in the announcement.
Hologic to go private post-deal
Blackstone and TPG will acquire all outstanding Hologic shares for US$76 per share in cash, plus a non-tradable contingent value right (CVR) to receive up to US$3 per share in two payments of up to US$1.50 each. The non-tradable CVR would be issued to Hologic stockholders at closing and paid following achievement of certain global revenue goals for Hologic’s Breast Health business in 2026 and 2027.
The aggregate purchase price represents a premium of approximately 46 per cent to Hologic’s closing price on May 23, 2025, the last full trading day prior to media reports regarding a possible transaction involving the company.
Upon completion of the transaction, Hologic’s common stock will be delisted from the Nasdaq stock market. The company will maintain its headquarters in Marlborough, and will continue to operate under the Hologic name and brand.
Stephen P MacMillan, Hologic’s Chairman, President and Chief Executive Officer, commented: “Today marks an exciting new chapter for Hologic as we join forces with the exceptional teams at Blackstone and TPG. Their resources, expertise and commitment to women’s health, will help accelerate our growth and enhance our ability to deliver critical medical technologies to customers and their patients around the world.
“This transaction delivers immediate and compelling value to Hologic stockholders, reflecting the dedication of our employees whose hard work has made this milestone possible.”
Ram Jagannath, a Senior Managing Director at Blackstone, added: “Hologic is an outstanding global leader in advancing women’s health, with a longstanding reputation for groundbreaking and high-quality medical device and diagnostic products.
“We have closely followed the company for many years and long admired the positive impact its life-changing technologies have had for millions of patients worldwide.”
Follow us on
